share_log

歌禮製藥-B：截至二零二三年十二月三十一日止年度之年度業績公告

ASCLETIS-B: ANNUAL RESULTS OF ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

香港交易所 ·  Mar 25 09:00
Summary by Moomoo AI
歌禮製藥有限公司（股份代號：1672）公布截至2023年12月31日止年度之經審核簡明綜合年度業績。該年度，集團收入約人民幣56.6百萬元，較2022年增加4.6%；毛利由2022年的約人民幣24.7百萬元虧損，轉為約人民幣26.0百萬元盈利。研發成本由約人民幣267.1百萬元減少18.8%至約人民幣216.8百萬元，主要由於臨床及臨床前項目研發效率提高及無形資產折舊及攤銷成本減少。年內虧損由約人民幣314.8百萬元減少至約人民幣144.7百萬元。集團現金及現金等價物以及定期存款約為人民幣2,274.6百萬元，預計足以支持至2028年的研發活動及營運。集團未派發任何股息，並於報告期內購回及註銷股份以提升股東價值。
歌禮製藥有限公司（股份代號：1672）公布截至2023年12月31日止年度之經審核簡明綜合年度業績。該年度，集團收入約人民幣56.6百萬元，較2022年增加4.6%；毛利由2022年的約人民幣24.7百萬元虧損，轉為約人民幣26.0百萬元盈利。研發成本由約人民幣267.1百萬元減少18.8%至約人民幣216.8百萬元，主要由於臨床及臨床前項目研發效率提高及無形資產折舊及攤銷成本減少。年內虧損由約人民幣314.8百萬元減少至約人民幣144.7百萬元。集團現金及現金等價物以及定期存款約為人民幣2,274.6百萬元，預計足以支持至2028年的研發活動及營運。集團未派發任何股息，並於報告期內購回及註銷股份以提升股東價值。
Song Pharmaceutical Co., Ltd. (stock code: 1672) announces audited condensed consolidated annual results for the year ended 31 December 2023. For the year, the Group's revenue was approximately RMB56.6 million, up 4.6% from 2022; gross profit translated from a loss of about RMB24.7 million in 2022 to a profit of approximately RMB26.0 million. R&D costs decreased 18.8% to approximately RMB216.8 million from approximately RMB267.1 million, mainly due to improved R&D efficiency in clinical and preclinical projects and lower intangible asset depreciation and amortization costs. Loss for the year decreased from approximately RMB314.8 million to approximately RMB144.7 million. The Group's cash and cash equivalents and fixed deposits of approximately RMB2,274.6 million are expected to support R&D activities and operations until 2028. The Group has not distributed any dividends and repurchased and written off shares during the reporting period to enhance shareholder value.
Song Pharmaceutical Co., Ltd. (stock code: 1672) announces audited condensed consolidated annual results for the year ended 31 December 2023. For the year, the Group's revenue was approximately RMB56.6 million, up 4.6% from 2022; gross profit translated from a loss of about RMB24.7 million in 2022 to a profit of approximately RMB26.0 million. R&D costs decreased 18.8% to approximately RMB216.8 million from approximately RMB267.1 million, mainly due to improved R&D efficiency in clinical and preclinical projects and lower intangible asset depreciation and amortization costs. Loss for the year decreased from approximately RMB314.8 million to approximately RMB144.7 million. The Group's cash and cash equivalents and fixed deposits of approximately RMB2,274.6 million are expected to support R&D activities and operations until 2028. The Group has not distributed any dividends and repurchased and written off shares during the reporting period to enhance shareholder value.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more